Can GPCRs Be Targeted to Control Inflammation in Asthma?
Publication/Presentation Date
1-1-2021
Abstract
Historically, the drugs used to manage obstructive lung diseases (OLDs), asthma, and chronic obstructive pulmonary disease (COPD) either (1) directly regulate airway contraction by blocking or relaxing airway smooth muscle (ASM) contraction or (2) indirectly regulate ASM contraction by inhibiting the principal cause of ASM contraction/bronchoconstriction and airway inflammation. To date, these tasks have been respectively assigned to two diverse drug types: agonists/antagonists of G protein-coupled receptors (GPCRs) and inhaled or systemic steroids. These two types of drugs "stay in their lane" with respect to their actions and consequently require the addition of the other drug to effectively manage both inflammation and bronchoconstriction in OLDs. Indeed, it has been speculated that safety issues historically associated with beta-agonist use (beta-agonists activate the beta-2-adrenoceptor (β
Volume
1304
First Page
1
Last Page
20
ISSN
0065-2598
Published In/Presented At
Sharma, P., & Penn, R. B. (2021). Can GPCRs Be Targeted to Control Inflammation in Asthma?. Advances in experimental medicine and biology, 1304, 1–20. https://doi.org/10.1007/978-3-030-68748-9_1
Disciplines
Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods
PubMedID
34019260
Department(s)
Administration and Leadership
Document Type
Article